They also found that targeting of TUG1 significantly reduces high-cholesterol diet-induced aortic valve calcification in ApoE−/− mice, which can provide evidence for a therapeutic strategy in CAVD treatment. The gene discussed is TUG1; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.